Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Tarceva

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tarceva was produced by Roche and Astellas.

AZ makes case for first-line Tagrisso therapy in lung cancer

AZ makes case for first-line Tagrisso therapy in lung cancer

AZ makes case for first-line Tagrisso therapy in lung cancer. Data shows the drug improved PFS versus older EGFR inhibitors including Roche’s Tarceva. ... Earlier data from FLAURA have shown that AZ’s drug improved progression-free survival (PFS)

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib line EGFR-mutated NSCLC market with Iressa and Roche's Tarceva (erlotinib), another first-generation drug, as well as newer agents like Boehringer Ingelheim’s Giotrif (afatinib).

Clock starts ticking on AZ’s first-line lung cancer filing in US

Clock starts ticking on AZ’s first-line lung cancer filing in US Third-generation EGFR inhibitor Tagrisso (osimertinib) is already approved as a follow-up to older drugs in the class, including AZ’s own Iressa (gefitinib) product and Roche's Tarceva (erlotinib), ... showed that Tagrisso extended progression-free

AZ speeds first-line lung cancer filing for Tagrisso to EMA

AZ speeds first-line lung cancer filing for Tagrisso to EMA AZ describes Tagrisso as a third-generation EGFR inhibitor, with advantages over first-line agents - its own Iressa (gefitinib) product and Roche's Tarceva (erlotinib) - not only in efficacy but also ... In FLAURA, the median duration of response was

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics